Anti-PD-1 antibodies and compositions

1. An anti-PD-1 antibody or an antigen-binding portion thereof, wherein said antibody comprises the H-CDR1-3 and L-CDR1-3 amino acid sequences of:

a) SEQ ID NOs: 29, 30, 31, 32, 33, and 34, respectively;

b) SEQ ID NOs: 35, 36, 37, 38, 39, and 40, respectively;

c) SEQ ID NOs: 41, 42, 43, 44, 45, and 46, respectively;

d) SEQ ID NOs: 29, 47, 48, 49, 50, and 51, respectively;

e) SEQ ID NOs: 52, 53, 54, 38, 45, and 55, respectively;

f) SEQ ID NOs: 29, 56, 48, 57, 33, and 51, respectively;

g) SEQ ID NOs: 58, 59, 60, 57, 33, and 34, respectively;

h) SEQ ID NOs: 61, 62, 43, 44, 45, and 46, respectively;

i) SEQ ID NOs: 63, 64, 65, 32, 33, and 34, respectively;

j) SEQ ID NOs: 66, 67, 68, 38, 45, and 55, respectively;

k) SEQ ID NOs: 69, 70, 71, 72, 45, and 73, respectively; or

l) SEQ ID NOs: 74, 75, 76, 57, 33, and 34, respectively.

2. The anti-PD-1 antibody or antigen-binding portion of claim 1 , wherein said antibody comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy and light chain variable domains have the amino acid sequences of:

a) SEQ ID NOs: 1 and 2, respectively;

b) SEQ ID NOs: 3 and 4, respectively;

c) SEQ ID NOs: 5 and 6, respectively;

d) SEQ ID NOs: 7 and 8, respectively;

e) SEQ ID NOs: 9 and 10, respectively;

f) SEQ ID NOs: 11 and 12, respectively;

g) SEQ ID NOs: 13 and 14, respectively;

h) SEQ ID NOs: 15 and 16, respectively;

i) SEQ ID NOs: 17 and 18, respectively;

j) SEQ ID NOs: 19 and 20, respectively;

k) SEQ ID NOs: 21 and 22, respectively; or

l) SEQ ID NOs: 23 and 24, respectively.

3. The anti-PD-1 antibody of claim 1 , wherein the antibody is of isotype IgG subclass IgG1.

4. The anti-PD-1 antibody of claim 3 , wherein the antibody comprises at least one mutation in the Fc region.

5. The anti-PD-1 antibody of claim 4 , wherein one or both of the amino acid residues at positions 234 and 235 are mutated to Ala.

6. The anti-PD-1 antibody or antigen-binding portion of claim 1 , wherein the antibody or portion has at least one of the following properties:

a) binds to cynomolgus PD-1 with a K D of 4×10 −8 M or less;

b) binds to mouse PD-1 with a K D of 2×10 −8 M or less;

c) binds to human PD-1 with a K D of 3×10 −9 M or less;

d) inhibits the interaction of PD-1 with PD-L1 at a concentration of 10 μg/ml;

e) stimulates IL-2 production in an SEB (Staphylococcal enterotoxin B) whole blood assay; and

f) stimulates IFN-γ production in a one-way mixed lymphocyte reaction assay.

7. A pharmaceutical composition comprising an anti-PD-1 antibody or antigen-binding portion thereof according to claim 1 and a pharmaceutically acceptable excipient.

8. A bi-specific binding molecule having the binding specificities of any two distinct anti-PD-1 antibodies or antigen-binding portions thereof according to claim 1 .

9. A method for enhancing immunity in a patient in need thereof, comprising administering to said patient the anti-PD-1 antibody or antigen-binding portion according to claim 1 .

10. The method of claim 9 , further comprising administering to the patient an immunostimulatory agent, a vaccine, a chemotherapeutic agent, an anti-neoplastic agent, an anti-angiogenic agent, a tyrosine kinase inhibitor, a PD-1 pathway inhibitor, or radiation therapy.

11. A method for treating cancer in a patient, comprising administering to said patient the antibody or antigen-binding portion according to claim 1 .

12. The method of claim 11 , wherein the cancer originates in a tissue selected from the group consisting of skin, lung, intestine, colon, ovary, brain, prostate, kidney, soft tissues, hematopoietic system, head and neck, liver, bladder, breast, stomach, uterus and pancreas.

13. The method of claim 11 , wherein the cancer is selected from the group consisting of advanced or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell cancer, bladder cancer, gastric cancer, renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, and Hodgkin's lymphoma.

14. An anti-PD-1 antibody that comprises:

a) a heavy chain (HC) with the amino acid sequences of SEQ ID NOs: 1 and 26 and a light chain (LC) with the amino acid sequences of SEQ ID NOs: 2 and 28;

b) an HC with the amino acid sequences of SEQ ID NOs: 3 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 4 and 28;

c) an HC with the amino acid sequences of SEQ ID NOs: 5 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 6 and 28;

d) an HC with the amino acid sequences of SEQ ID NOs: 7 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 8 and 28;

e) an HC with the amino acid sequences of SEQ ID NOs: 9 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 10 and 28;

f) an HC with the amino acid sequences of SEQ ID NOs: 11 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 12 and 28;

g) an HC with the amino acid sequences of SEQ ID NOs: 13 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 14 and 28;

h) an HC with the amino acid sequences of SEQ ID NOs: 15 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 16 and 28;

i) an HC with the amino acid sequences of SEQ ID NOs: 17 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 18 and 28;

j) an HC with the amino acid sequences of SEQ ID NOs: 19 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 20 and 28;

k) an HC with the amino acid sequences of SEQ ID NOs: 21 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 22 and 28; or

l) an HC with the amino acid sequences of SEQ ID NOs: 23 and 26 and an LC with the amino acid sequences of SEQ ID NOs: 24 and 28.

15. An anti-PD-1 antibody that comprises a heavy chain (HC) with the amino acid sequences of SEQ ID NOs: 9 and 26 and a light chain (LC) with the amino acid sequences of SEQ ID NOs: 10 and 28.

16. A pharmaceutical composition comprising an anti-PD-1 antibody according to claim 15 and a pharmaceutically acceptable excipient.

17. A method for enhancing immunity in a patient in need thereof, comprising administering to said patient the anti-PD-1 antibody according to claim 15 .

18. The method of claim 17 , further comprising administering to the patient an immunostimulatory agent, a vaccine, a chemotherapeutic agent, an anti-neoplastic agent, an anti-angiogenic agent, a tyrosine kinase inhibitor, a PD-1 pathway inhibitor, or radiation therapy.

19. A method for treating cancer in a patient, comprising administering to said patient the antibody according to claim 15 .

20. The method of claim 19 , wherein the cancer

a) originates in a tissue selected from the group consisting of skin, lung, intestine, colon, ovary, brain, prostate, kidney, soft tissues, hematopoietic system, head and neck, liver, bladder, breast, stomach, uterus and pancreas; or

b) is selected from the group consisting of advanced or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell cancer, bladder cancer, gastric cancer, renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, and Hodgkin's lymphoma.